research Transient hair loss in patients with chronic spontaneous urticaria treated with omalizumab
Omalizumab can cause temporary hair loss but still works well for chronic urticaria.
Search
for
Sort by
Research
30 / 1000+ resultsresearch Alopecia Areata after Omalizumab Treatment for Chronic Spontaneous Urticaria
Omalizumab may cause hair loss.
research Spectrum and Impact of Reported Side Effects of Omalizumab in Patients With Chronic Urticaria: A Long‐Term Multicentre Real‐World Study
Omalizumab is generally safe for chronic urticaria, but hair loss is a common side effect.
research Case Report: Omalizumab-associated hair loss: a case of eyebrow alopecia areata, literature review and FAERS database analysis
Omalizumab may cause temporary hair loss, especially in women aged 18-60.
research The most common pediatric and adult dermatology patient complaints in a month of the COVID‐19 pandemic in Turkey
During the COVID-19 pandemic in Turkey, the most common skin problem for both kids and adults was acne.
research Biologics in the management of childhood atopic dermatitis
Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
research Adverse Reactions to Biologic Medications Used in Allergy and Immunology Diseases
Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.
research Cytokine-targeted treatment in alopecia areata - new possibilities?
New cytokine-targeted therapies show promise for treating alopecia areata.
research Understanding the Intricate Pathophysiology of Psoriasis and Related Skin Disorders
Psoriasis involves immune and genetic factors, and understanding these can improve treatments.
research Issue Information
The document summarized various dermatology studies and case reports.
research Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database
Biologics for severe asthma have known side effects, but some new risks need more study.
research Research Progress in Chronic Autoimmune Urticaria
Chronic autoimmune urticaria can be managed with specific therapies and requires improved diagnosis and treatment methods.
research Alopecia areata after mogamulizumab treatment
Mogamulizumab can cause hair loss and skin rashes.
research Mogamulizumab‐induced alopecia. Multicentric case series: Clinical, trichoscopic and histological characterization
Mogamulizumab can cause hair loss, often linked to a better treatment response.
research Nemolizumab Treatment for Severe Atopic Dermatitis Led to the Simultaneous Improvement of Coexisting Refractory Alopecia Areata: A Case Report
Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.
research Psoriatic Alopecia and Paradoxical Psoriasis Induced by Adalimumab Successfully Treated with Certolizumab: Clinical, Trichoscopic, and in vivo Reflectance Confocal Microscopy Features
Certolizumab effectively treats psoriasis and psoriatic arthritis with fewer side effects than adalimumab.
research Daclizumab
Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.
research Sycosis Barbae Treated With Bimekizumab
Bimekizumab effectively treated a man's chronic beard hair loss.
research Efalizumab-induced hypertrichosis
Efalizumab can cause unexpected excessive hair growth.
research An occurrence of eosinophilic folliculitis and alopecia associated with a sustained complete response to mogamulizumab in Sézary syndrome: a case report
Mogamulizumab treatment in Sézary syndrome may cause skin issues and hair loss but can lead to a complete response.
research Skin Lesions in a Daclizumab-treated Patient with Multiple Sclerosis
A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.
research Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
Ixekizumab has known and some unexpected side effects.
research 44047 Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
research Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis
Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.
research Case Report: Bimekizumab for dissecting cellulitis of the scalp
Bimekizumab effectively treats scalp cellulitis and improves quality of life.
research Treatment of chronic alopecia areata with tildrakizumab: an open‐label pilot study
Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
research New Drugs: Eculizumab
Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.
research Delayed Onset of Alopecia Areata in a Patient on Ocrelizumab for Multiple Sclerosis: A Case Report
Ocrelizumab may cause delayed hair loss in some patients.
research Real-world single-center experience with 10 cases of generalized pustular psoriasis successfully treated with ixekizumab
Ixekizumab effectively treats generalized pustular psoriasis.
research 128 Bimekizumab led to rapid & deep normalisation of molecular signatures associated with PASI sub-components, preceding clinical skin clearance
Bimekizumab quickly improves psoriasis symptoms and skin at the molecular level.